top of page
PRESS
Newly Granted Patent Application improves Patient Compliance
Newly Granted Patent Application improves Patient Compliance
May 27, 20252 min read
Recardio signs letter of intent with Kancera for licensing of cardiometabolic assets
San Francisco, March 7, 2025 - Recardio Inc., a late clinical-stage life science company developing therapies for cardiovascular and other diseases, today announced that the company has signed a letter of intent for a planned license agreement with the public Swedish biotech company, Kancera AB (Kancera). Kancera and Recardio have agreed to evaluate combining both companies’ assets and resources through a transaction in which Recardio would in-license drug candidates, KAND567
Mar 7, 20253 min read
Recardio at J.P. Morgan 2025
San Francisco, January 9, 2025 - Recardio Inc., a late-stage clinical-stage life science company focusing on therapies for cardiovascular...
Jan 9, 20251 min read
bottom of page